Land: Nederland
Taal: Nederlands
Bron: CBG-MEB (College ter Beoordeling van Geneesmiddelen)
FLURBIPROFEN
Sandoz B.V.
R02AX01
FLURBIPROFEN
Tablet
BETACAROTEEN (E 160a (II)) ; BLOEDSINAASAPPELSMAAKSTOF ; BUTYLHYDROXYANISOL (E 320) ; ISOMALT (E 953) ; KALIUMHYDROXIDE (E 525) ; LEVOMENTHOL (L- Vorm) ; MACROGOL 300 ; MALTITOL, VLOEIBAAR (E 965) ; SINAASAPPELSMAAKSTOF ; SUCRALOSE (E 955),
Oromucosaal gebruik
Flurbiprofen
Hulpstoffen: BETACAROTEEN (E 160a (II)); BLOEDSINAASAPPELSMAAKSTOF; BUTYLHYDROXYANISOL (E 320); ISOMALT (E 953); KALIUMHYDROXIDE (E 525); LEVOMENTHOL (L- Vorm); MACROGOL 300; MALTITOL, VLOEIBAAR (E 965); SINAASAPPELSMAAKSTOF; SUCRALOSE (E 955);
2016-10-05
PACKAGE LEAFLET: INFORMATION FOR THE PATIENT Flurbiprofen Sandoz sinaasappel suikervrij 8,75 mg, zuigtabletten Flurbiprofen_ _ READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. - If you get any side effects, talk to your doctor. This includes any possible side effects not listed in this leaflet. See section 4. READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. Always take this medicine exactly as described in this leaflet or as your doctor or pharmacist has told you. - Keep this leaflet. You may need to read it again. - Ask your pharmacist if you need more information or advice. - If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. - You must talk to a doctor if you do not feel better or if you feel worse after 3 days. WHAT IS IN THIS LEAFLET 1. What [Nationally completed name] is and what it is used for 2. What you need to know before you take [Nationally completed name] 3. How to take [Nationally completed name] 4. Possible side effects 5. How to store [Nationally completed name] 6. Contents of the pack and other information 1. WHAT {[NATIONALLY COMPLETED NAME]} IS AND WHAT IT IS USED FOR {[Nationally completed name]}contains flurbiprofen. It belongs to a group of medicines known as non-steroidal anti-inflammatory drugs (NSAIDs). NSAIDs provide relief by changing the body’s response to pain, swelling, and high temperature. {[Nationally completed name]} lozenges are used for the short-term relieve of symptoms of sore throat such as throat pain and soreness in adults and children over the age of 12 years. You must talk to Lees het volledige document
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Flurbiprofen Sandoz sinaasappel suikervrij 8,75 mg, zuigtabletten 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each lozenge contains 8.75 mg Flurbiprofen. Excipient(s) with known effect Isomalt 2160 mg/lozenge Maltitol 383 mg/lozenge Butylated hydroxyanisole (E320) 0.013 mg/lozenge For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Lozenge Round, orange lozenge with typical line marking and without debossment, orange flavour. Diameter: Approximately 19 mm 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS {[Nationally completed name] 8.75 mg lozenges} are indicated for the short term symptomatic relief of sore throat in adults and children over the age of 12 years. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Posology _ _ _Adults, the elderly and children over the age of 12 years _ One lozenge sucked/dissolved slowly in the mouth every 3-6 hours as required. Maximum 5 lozenges in a 24 hour period. It is recommended that this product should be used for a maximum of three days. _Pediatric population _ Not indicated for children under 12 years. _Elderly _ A general dose recommendation cannot be given, since to date clinical experience is limited. The elderly are at increased risk of the serious consequences of adverse reactions. _Hepatic impairment _ In patients with mild to moderate impairment of hepatic function no dose reduction is required. In patients with severe hepatic insufficiency flurbiprofen is contraindicated (see section 4.3). _Renal impairment _ In patients with mild to moderate impairment of renal function no dose reduction is required. In patients with severe renal insufficiency flurbiprofen is contraindicated (see section 4.3). Method of administration _ _ For oromucosal administration and short-term use only. As with all lozenges, to avoid local irritation, {[nationally completed name]} should be moved around the mouth whilst sucking. The lowest effective dose should be administered for the shortest duration nece Lees het volledige document